Innovation / / 5 min read

WHO Global Tuberculosis Report 2026: Domestic Funding Rises 14% to $5.6 Billion as Six-Month Drug-Resistant Treatment Uptake More Than Doubles

WHO reported 10.6 million new TB cases and 1.1 million deaths in 2025, with domestic budgets rising 14% to $5.6 billion amid international donor cuts and six-month RR-TB regimen uptake jumping to 42%, though R&D funding lags below a quarter of target.

By 全球伯乐 News

Source compilation

Share
On this page

Global tuberculosis (TB) deaths declined to an estimated 1.1 million in 2025 alongside 10.6 million new cases, while domestic government funding rose 14% between 2024 and 2025 to reach US$ 5.6 billion, according to the World Health Organization (WHO) Global Tuberculosis Report 2026 release published on November 121. That domestic budget expansion partially offset a pullback of comparable scale in international donor financing—following global health aid retrenchment by major bilateral donors including the United States—preserving essential clinical services for a disease that has seen 86 million lives saved through treatment since 2000 yet remains the world's deadliest single infectious agent1.

AI-generated editorial illustration of a glass Erlenmeyer flask, a brushed-brass calibration weight, and two sage-and-ivory capsules on frosted glass and travertine

AI-generated editorial illustration: a clear glass Erlenmeyer flask and brushed-brass calibration weight on frosted glass alongside two sage-and-ivory capsules on travertine stone represent domestic tuberculosis financing, rapid diagnostics, and six-month oral treatment regimens, not a real clinical or pharmaceutical facility photograph.

Mortality Falls 35% Since 2015 to Hit Delayed Milestone Amid Sharp Regional Divergence

Data compiled in the WHO Global Tuberculosis Report 2026 announcement show that the 35% reduction in annual TB deaths between 2015 and 2025 finally achieved the first mortality milestone of WHO's End TB Strategy, albeit five years behind schedule1. By contrast, the global TB incidence rate per 100,000 population fell by only 14% over the same decade, falling well short of the 50% reduction milestone originally set for 20251.

Disease burden remains heavily concentrated in 30 high-burden countries accounting for 88% of all people who developed TB in 2025, with starkly uneven regional trajectories1. Between 2015 and 2025, TB incidence dropped 42% in the WHO European Region and 30% in the African Region, compared with declines of 18% in South-East Asia, 6.6% in the Eastern Mediterranean, and 0% net change in the Western Pacific; in the Region of the Americas, incidence rose for the fifth consecutive year to stand 13% above 2015 levels1.

Diagnostic Gaps Leave 2.2 Million Undetected While Short-Course Drug-Resistant Regimens Surge

Across frontline care delivery, the November 12 WHO report highlights persistent screening bottlenecks alongside rapid adoption of newer therapeutic protocols. Of the estimated 10.6 million individuals who fell ill with TB in 2025, 8.4 million were formally diagnosed and notified, leaving roughly 2.2 million patients either undiagnosed or unreported1. Furthermore, only 59% of newly diagnosed patients were initially tested with a WHO-recommended rapid molecular diagnostic assay, trailing the 100% universal rapid-testing target established for 20271.

In drug-resistant care, an estimated 370,000 people developed rifampicin-resistant TB (RR-TB) in 2025, with overall treatment coverage still constrained at 42%1. Among RR-TB patients enrolled in care, however, uptake of the WHO-recommended six-month all-oral treatment regimen more than doubled within a single year—climbing from 18% in 2024 to 42% in 2025—demonstrating that clinical health systems can rapidly deploy shorter, higher-adherence pharmaceutical innovations once procurement channels are established1.

Domestic Budgets Cushion Donor Retrenchment, Yet Global R&D Lags Below One Quarter of Target

WHO Director-General Dr. Tedros Adhanom Ghebreyesus noted in the official release that national governments have dug deeper into domestic budgets to safeguard hard-won gains amid external funding cuts, while stressing that losing over one million lives annually to a preventable and curable illness remains unacceptable1. Although the US$ 5.6 billion domestic allocation cushioned immediate clinic disruptions, fiscal constraints in lower-income countries limit how fast domestic treasuries alone can expand active case-finding and molecular laboratory networks1.

The sharpest structural shortfall lies in biomedical research and industrial innovation: global funding for TB research stood at just US$ 1.2 billion in 2023, representing less than one quarter of the US$ 5 billion annual requirement set for 20271. Without sustained public-private R&D commitments to advance late-stage vaccine candidates, point-of-care diagnostics, and next-generation regimens, incremental service delivery gains alone will remain insufficient to bend global incidence curves onto the End TB trajectory1.

Source notes

  1. 2026-11-12 · Amid challenges, countries increase domestic investment to protect progress against tuberculosis · World Health Organization (WHO). ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14

Keep reading

More from the desk

Studio tabletop still life of three graduated brushed-brass blocks, a clear glass prism, and a dark green jadeite cylinder on veined white marble
Business/

EU Strikes Deal on Three-Tier 70% SFDR Sustainable Fund Categories as IMF Closes 58% of Open IEO Reform Actions

The Council of the European Union and the European Parliament reached a provisional agreement overhauling the Sustainable Finance Disclosure Regulation into sustainable, transition, and ESG basics categories with a 70% minimum investment threshold, while the IMF Executive Board concluded its 16th Periodic Monitoring Report on Independent Evaluation Office recommendations.

Studio tabletop still life of a clear glass microfluidic flow-cell slide, two amber glass reagent ampoules, and a brass cylinder on pale travertine stone
Innovation/

FDA Reviews Pathogen-Agnostic Sequencing Diagnostics as WHO GAP-f Advances Pediatric Medicines Roadmap and WIPO Signs 2027–2029 India IP Plan

The U.S. Food and Drug Administration Microbiology Devices Panel convened to evaluate pathogen-agnostic sequencing and agile bioinformatics for outbreak response, while the World Health Organization highlighted GAP-f pediatric formulation targets on World Children's Day and WIPO signed the 2027–2029 IP Action Plan with India covering AI analytics and dispute resolution.

Studio tabletop still life of three brushed-brass cylinders in a triangle around a faceted optical crystal polyhedron and a dark obsidian bar on grey limestone
Current Affairs/

China, Russia, and U.S. Issue Shenzhen Trilateral Peace Declaration as Second EU-UK Summit and Dublin BIIGC Adopt Joint Statements

Presidents Xi Jinping, Vladimir Putin, and Donald Trump held their first trilateral summit in Shenzhen and issued a four-point Peace Declaration on UN reform, refined petroleum supply, state official immunity, and nuclear risk reduction, while European and British leaders concluded the second EU-UK Summit in Brussels and the British-Irish Intergovernmental Conference in Dublin.